The Claria MRI CRT-D contains built-in software that uses an algorithm to assess the effectiveness of pulses sent to a patient’s heart and adjust the rate of the pulses accordingly, according to a news release.
“Until now, CRT devices have shown only whether a pacing pulse was sent, but we haven’t been able to determine if that stimulation actually improves the heart’s pumping ability,” said Suneet Mittal, MD, director of the Electrophysiology Laboratory at the Arrhythmia Institute of Valley Health System in Ridgewood, N.J. “Physicians are now able to verify the effectiveness of left ventricular pacing, which is especially beneficial for improving outcomes in patients with atrial fibrillation.”
Medtronic did not indicate when the device would hit the market.
More articles on supply chain:
FDA rejects Dynavax’s hep B vaccine…again
How will President-elect Donald Trump’s policies affect medtech and pharma?
Novartis’ leukemia drug earns priority review status
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
